

## VIRTUAL SATELLITE SYMPOSIUM


# Sequencing of therapies in high-risk relapsed/refractory lymphoma and CLL

June 18, 2021



Lymphoma Hub is delivered by SES

 **Scientific Education Support**






# Welcome and introductions

**Professor Gilles Salles**

Memorial Sloan Kettering Cancer Center

New York, US



# Speakers

---



**GILLES SALLES**  
Memorial Sloan Kettering  
Cancer Center  
New York, US



**FRANCESC BOSCH**  
University Hospital  
Vall d'Hebron  
Barcelona, ES



**LORETTA NASTOUPIL**  
MD Anderson Cancer Center  
Houston, US



**STEVEN LE GOUILL**  
CHU de Nantes  
Nantes, FR




**ANDREW DAVIES**  
University of  
Southampton  
Southampton, UK

# Agenda

---

Time (CEST)	Item	Speaker
18:00–18:05	Welcome and introductions	Chair: Gilles Salles
18:05–18:20	Treatment options for a patient with ibrutinib-resistant CLL	Francesc Bosch
18:20–18:35	How to treat early relapse in a patient with FL	Loretta Nastoupil
18:35–18:50	Sequencing of therapy for a patient with <i>TP53</i> -mutated MCL	Steven Le Gouill
18:50–19:05	Sequencing treatment options in primary refractory DLBCL	Andrew Davies
19:05–19:25	Roundtable discussion	All
19:25–19:30	Meeting conclusion	Chair: Gilles Salles

# Overview of lymphoma and CLL drug approvals, 2020–2021



BL, Burkitt lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; FL, follicular lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; YA, young adult.